Neurocrine Biosciences
NBIX
#1644
Rank
HK$104.95 B
Marketcap
HK$1,043
Share price
3.77%
Change (1 day)
33.57%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): HK$37.58

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is HK$37.75. an increase over its 2024 EPS that were of HK$26.47.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025HK$36.4937.87%
2024HK$26.4733.07%
2023HK$19.8957.76%
2022HK$12.6169.47%
2021HK$7.44-78.21%
2020HK$34.14990%
2019HK$3.1381.82%
2018HK$1.72-113.5%
2017-HK$12.760.62%
2016-HK$12.6957.28%
2015-HK$8.0725.61%
2014-HK$6.4218.84%
2013-HK$5.40-1085.71%
2012HK$0.55

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
HK$10.65-71.78%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
HK$18.73-50.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$180.31 377.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
HK$6.81-81.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-HK$15.90-142.12%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
HK$13.39-64.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-HK$234.15-720.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
HK$13.75-63.56%๐Ÿ‡ฌ๐Ÿ‡ง UK